<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03055910</url>
  </required_header>
  <id_info>
    <org_study_id>FFR_01_2017</org_study_id>
    <nct_id>NCT03055910</nct_id>
  </id_info>
  <brief_title>Fractional Flow Reserve Fax Registry</brief_title>
  <acronym>F(FR)²</acronym>
  <official_title>A Fax-based Registry Regarding Clinical Indications, Complication Rates and Management Consequences of Invasive Fractional Flow Reserve Measurements</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Erlangen-Nürnberg Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abbott Medical Devices</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Erlangen-Nürnberg Medical School</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Fractional Flow Reserve Fax Registry is an investigator-initiated, real-world registry to&#xD;
      analyze the use of fractional flow reserve (FFR) measurements in clinical practice in cardiac&#xD;
      catheterization laboratories in Germany. The registry aims to collect the data of 2000&#xD;
      patients who underwent FFR recordings for clinical reasons. The main outcome parameter is the&#xD;
      frequency of coronary revascularization following FFR. Secondary outcome parameters include&#xD;
      the distribution of quantitative FFR results in clinical practice, the influence of&#xD;
      intracoronary versus intravenous adenosine on the distribution of FFR results, the rate of&#xD;
      complications as a result of FFR measurements, the average number of FFR wires needed per&#xD;
      patient. Since the study will include a large number of patients who undergo i.c.&#xD;
      administration of adenosine and a large number of patients who undergo i.v. administration of&#xD;
      adenosine, it will be possible to analyze whether the route of adenosine administration is an&#xD;
      independent predictor of the FFR result.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patient Inclusion Criteria&#xD;
&#xD;
      All patients who undergo measurement of the Fractional Flow Reserve using intracoronary&#xD;
      pressure measurements for clinical reasons are eligible for inclusion.&#xD;
&#xD;
      There are no exclusion criteria.&#xD;
&#xD;
      Methods&#xD;
&#xD;
      Following a clinically indicated FFR measurement, patient data and data concerning&#xD;
      angiographic stenosis severity as well as anatomic location of the interrogated lesion,&#xD;
      method of adenosine administration, and FFR result are documented in a paper form. The form&#xD;
      contains no patient data except age and gender as well as the cath lab identifying number and&#xD;
      the serial number of the used FFR wire(s). The paper form is transmitted by fax to the&#xD;
      central study site at Erlangen University where data will be stored and all evaluations will&#xD;
      be performed.&#xD;
&#xD;
      Recruitment period&#xD;
&#xD;
      Recruitment starts March 1, 2017 and will be terminated after 2000 patients have been&#xD;
      included.&#xD;
&#xD;
      Number of patients&#xD;
&#xD;
      2000 patients will be included.&#xD;
&#xD;
      Outcome parameters&#xD;
&#xD;
      The main outcome parameter is the frequency of coronary revascularization following FFR.&#xD;
&#xD;
      Secondary outcome parameters include the distribution of quantitative FFR results in clinical&#xD;
      practice, the rate of complications as a result of FFR measurements, and the average number&#xD;
      of FFR wires needed per patient, as well as the influence of i.c. versus i.v. administration&#xD;
      of adenosine on the distribution of obtained FFR results.&#xD;
&#xD;
      All outcome parameters will be determined immediately after the end of invasive coronary&#xD;
      angiography (and coronary intervention, if performed) in each patient (day 0). No follow-up&#xD;
      will be performed.&#xD;
&#xD;
      Institutional Review Board (IRB)&#xD;
&#xD;
      The study protocol has been approved by the IRB of the Faculty of Medicine, University of&#xD;
      Erlangen-Nürnberg (File Number 4_15B). Patient consent has been waived since data will be&#xD;
      completely anonymized and no study-specific interventions are performed.&#xD;
&#xD;
      Primary Investigator&#xD;
&#xD;
      The study primary investigator is&#xD;
&#xD;
      Stephan Achenbach&#xD;
&#xD;
      Department of Cardiology&#xD;
&#xD;
      University of Erlangen&#xD;
&#xD;
      Ulmenweg 18&#xD;
&#xD;
      91054 Erlangen&#xD;
&#xD;
      Germany&#xD;
&#xD;
      The study co-primary investigator is&#xD;
&#xD;
      Helge Möllmann&#xD;
&#xD;
      Department of Cardiology&#xD;
&#xD;
      Johannes Hospital Dortmund&#xD;
&#xD;
      Johannesstraße 9-13&#xD;
&#xD;
      44137 Dortmund&#xD;
&#xD;
      Germany&#xD;
&#xD;
      Sponsor&#xD;
&#xD;
      The study is sponsored by the University Hospital Erlangen, Department of Cardiology. It is&#xD;
      financed through a restricted grant by Abbott Vascular&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">March 1, 2017</start_date>
  <completion_date type="Anticipated">January 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2018</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Day</target_duration>
  <primary_outcome>
    <measure>Revascularization</measure>
    <time_frame>1 hour</time_frame>
    <description>Rate of revascularization following measurement of the fractional flow reserve</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complications</measure>
    <time_frame>1 hour</time_frame>
    <description>Complication attributable to the invasive measurement of fractional flow reserve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of wires</measure>
    <time_frame>1 hour</time_frame>
    <description>Number of FFR wires used per patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Administration route</measure>
    <time_frame>1 hour</time_frame>
    <description>Average FFR values obtained in the cohort when using intracoronary or intravenous injection of adenosine</description>
  </secondary_outcome>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Coronary Artery Disease</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Fractional Flow Reserve Measurement</intervention_name>
    <description>Wire-based invasive measurement of the fractional flow reserve in the context of coronary angiography and percutaneous coronary intervention in order to assess the hemodynamic relevance of coronary artery stenoses</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients with known or suspected coronary artery disease in whom invasive fractional&#xD;
        flow reserve measurement is performed for clinical reasons in the context of coronary&#xD;
        angiography or percutaneous coronary intervention&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  invasive fractional flow reserve measurement is performed for clinical reasons&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  none&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephan Achenbach, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Friedrich Alexander University Erlangen-Nuremberg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stephan Achenbach, MD</last_name>
    <phone>++4991318535301</phone>
    <email>stephan.achenbach@uk-erlangen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Grit Herrmann</last_name>
    <phone>++4991318535301</phone>
    <email>grit.herrmann@uk-erlangen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>St. Johannes Hospital</name>
      <address>
        <city>Dortmund</city>
        <zip>44137</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Helge Moellmann, MD, PhD</last_name>
      <phone>++49231184335111</phone>
      <email>helge.moellmann@joho-dortmund.de</email>
    </contact>
    <contact_backup>
      <last_name>Agnes Steinborn</last_name>
      <phone>++49231184335111</phone>
      <email>inneremedizin1@joho-dortmund.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Stephan Achenbach, MD</last_name>
      <phone>++4991318535301</phone>
      <email>stephan.achenbach@uk-erlangen.de</email>
    </contact>
    <contact_backup>
      <last_name>Grit Herrmann</last_name>
      <phone>++4991318535301</phone>
      <email>grit.herrmann@uk-erlangen.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <study_first_submitted>February 14, 2017</study_first_submitted>
  <study_first_submitted_qc>February 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 16, 2017</study_first_posted>
  <last_update_submitted>February 15, 2017</last_update_submitted>
  <last_update_submitted_qc>February 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

